Added to YB: 2026-09-02
Pitch date: 2026-08-28
MRNA [bullish]
Moderna, Inc.
+15.04%
current return
Author Info
No bio for this author
Company Info
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
Market Cap
$55.1B
Pitch Price
$134.10
Price Target
N/A
Dividend
N/A
EV/EBITDA
-23.47
P/E
-17.23
EV/Sales
22.20
Sector
Biotechnology
Category
growth
Biotech Is the Biggest AI Winner — Moderna Just Proved It
MRNA (update): Moderna’s partnered Phase 3 success for individualized melanoma therapy intismeran supports the central thesis that its mRNA platform can extend beyond infectious-disease vaccines. Combined with Merck’s Keytruda, the therapy improved post-surgery outcomes versus Keytruda alone, sending shares up 177%. A filing, a likely 2027 approval push and readouts in larger cancers offer the path forward, but approval and pipeline success remain uncertain.
Read full article (7 min)